Abstract：Renal cell carcinoma is the most common malignant tumor of the kidney and its morbidity is increasing year by year. Because screening isn't all-pervading,some renal cancer patients have suffered metastatic lesions while they are diagnosed. Targeted drugs significantly prolonged survival in patients with advanced renal cell carcinoma. But not all of patients can benefit from that. Even a few patients suffer fatal adverse events during therapy, owing to individual differences of targeted drugs' efficacy and toxicity. So precise targeted individualized therapy strategy is particularly significant. This review will do a tentative explore on individualized management strategy of targeted therapy for advanced renal cell carcinoma.
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2015,65(1):5-29. [2] Motzer RJ, Agarwal N, Beard C, et al. Kidney cancer. J Natl Compr Cancer Netw, 2011,9(9):960-977. [3] 那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南手册.北京:人民卫生出版社,2014:3-19. [4] de Velasco G, Hamieh L, Mickey S, et al. Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol, 2015,33(12):538-545. [5] 范阳.靶向治疗在晚期肾癌中的应用现状和研究进展.微创泌尿外科杂志,2015,4(5):315-320. [6] 梅国徽,麦海星,徐小洁,等.肾癌靶向药物治疗耐药的研究进展.微创泌尿外科杂志,2015,4(5):309-314. [7] Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer,version 3.2015. J Natl Compr Canc Netw, 2015,13(2):151-159. [8] Flanigan RC, Salmon SE, Blumenstein B, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med, 2001,345(23):1655-1659. [9] Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma:a randomized trial. Lancet, 2001,358(9286):966-970. [10] 黄庆波.晚期肾癌的转移机制及治疗方式.微创泌尿外科杂志,2015,4(1):58-62. [11] Roti G, Stegmaier K. Genetic and proteomic approaches to identify cancer drug targets. Br J Cancer, 2012,106(2):254-261. [12] 叶定伟,郭军,施国海,等.中国晚期肾癌靶向治疗不良反应管理专家共识.中国癌症杂志,2015,25(8):561-565. [13] Li XS, Wu X, Zhao PJ, et al. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin Med J (Engl), 2011,124(18):2920-2924. [14] Tomita Y, Shinohara N, Yuasa T, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol, 2010,40(12):1166-1172. [15] 郭刚,张帆,张旭.肾细胞癌患者VEGFR3基因及CYP3A5*1基因单核苷酸多态性研究.临床泌尿外科杂志,2015,30(2):115-119. [16] Diekstra MH, Klümpen HJ, Lolkema MP, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther, 2014,96(1):81-89. [17] Kim JJ, Vaziri S, Rini B, et al. Associating of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal carcinoma patients treated with sunitinib. Cancer, 2012,118(7):1946-1954. [18] van Erp NP, Mathijssen RH, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol,2009,27(26):4406-4412. [19] Eechoute K, van der Veldt AA, Oosting S, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther, 2012,92(4):503-510. [20] Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol, 2011,12(12):1143-1150. [21] Diekstra M, Swen JJ, Boven E, et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol, 2015,68(4):621-629. [22] 李恩惠,夏术阶.晚期肾癌靶向治疗的现状与进展.现代肿瘤医学,2012,20(7):1514-1518. [23] Kollmannsbmger C, Soulieres D, Wang R, et al. Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. Can Urol Assoc, 2007,1(2):41-54. [24] Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase Ⅲ trial. Lancet, 2007,370 (9605):2103-2111. [25] Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol, 2008,19(8):1387-1392. [26] Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010,28(6):1061-1068. [27] 熊戴群.肾癌分子靶向治疗药物的不良反应及处理研究进展.肿瘤预防与治疗,2013,26(4):235-239. [28] Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA, 2008,300(19):2277-2285. [29] Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res, 2009,15(7):2497-2506. [30] Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 2003,9(1):327-337. [31] Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clini Oncol, 2012,30(32):4017-4025. [32] Olivera-Fernandez R, Fernandez-Ribeiro F, Pineiro-Corrales G, et al. Adherence to oral antineoplastic therapy. Farm Hosp, 2014,38(6):475-481.
